Edition:
United States

Eleven Biotherapeutics Inc (EBIO.OQ)

EBIO.OQ on NASDAQ Stock Exchange Global Market

1.91USD
20 Apr 2018
Change (% chg)

$0.29 (+17.90%)
Prev Close
$1.62
Open
$1.68
Day's High
$1.91
Day's Low
$1.64
Volume
1,032,302
Avg. Vol
237,416
52-wk High
$2.00
52-wk Low
$0.63

Chart for

About

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company's product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and... (more)

Overall

Beta: 3.10
Market Cap(Mil.): $60.80
Shares Outstanding(Mil.): 31.83
Dividend: --
Yield (%): --

Financials

  EBIO.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -1.13 -- --
ROI: -34.05 -0.74 13.19
ROE: -102.38 -2.80 15.00

BRIEF-Eleven Biotherapeutics Reports Q4 Loss Per Share $0.22

* ELEVEN BIOTHERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 OPERATING RESULTS AND VICINIUM DEVELOPMENT PROGRESS

Apr 04 2018

BRIEF-Eleven Biotherapeutics To Present Early Data From Bladder Cancer Trial In May

* PRELIMINARY DATA FROM PHASE 3 VISTA TRIAL IN BLADDER CANCER TO BE PRESENTED IN A PLENARY SESSION AT AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING

Apr 03 2018

BRIEF-Eleven Biotherapeutics Announces Pricing Of $10.0 Million Offering Priced At-The-Market

* ELEVEN BIOTHERAPEUTICS ANNOUNCES PRICING OF $10.0 MILLION OFFERING PRICED AT-THE-MARKET

Mar 21 2018

BRIEF-Eleven Biotherapeutics Files For Mixed Shelf Of Upto $150 Mln

* ELEVEN BIOTHERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text: (http://bit.ly/2u2wguN) Further company coverage:

Mar 19 2018

BRIEF-Eleven Biotherapeutics Says Completed Enrollment For Late-Stage Bladder Cancer Study

* ENROLLMENT COMPLETED IN PHASE 3 REGISTRATION TRIAL FOR NON-MUSCLE INVASIVE BLADDER CANCER

Mar 12 2018

BRIEF-Eleven Biotherapeutics Appoints Richard Fitzgerald As CFO

* ELEVEN BIOTHERAPEUTICS APPOINTS RICHARD FITZGERALD AS CHIEF FINANCIAL OFFICER

Jan 24 2018

BRIEF-Eleven Biotherapeutics reports Q3 loss per share $0.37

* Eleven Biotherapeutics reports third quarter 2017 financial results

Nov 20 2017

BRIEF-Eleven Biotherapeutics files for non timely 10-Q

* Eleven biotherapeutics inc files for non timely 10-Q - Sec Filing‍​ Source text: (http://bit.ly/2zZDGkA) Further company coverage:

Nov 15 2017

Earnings vs. Estimates